Xu Min, Tian Ying-Zhou, Zhu Xiu-Jun, Hu Xiang-Dan, He Tian-Tian
Gyhnecology Department of Second Clinical Medical College of Guangzhou University of CM, Guangzhou 510120, Guangdong Province, China.
Zhongguo Zhen Jiu. 2013 Mar;33(3):213-7.
To observe clinical efficacy of plum-blossom needle for follicular maldevelopment (FM).
Fifty cases of FM were randomly divided into a plum-blossom needle group and a medication group, 25 cases in each one. In the plum-blossom needle group, the plum-blossom needle was applied along Thoroughfare, Conception, Governor and Belt Vessel as well as at Pishu (BL 20), Weishu (BL 21), Shenshu (BL 23), Luanchao (Extra), Zigong (EX-CA 1) during the follicular growth phase, once every other day. In the medication group, clomifene (CC) was prescribed for oral administration and human choriogonadotropin (HCG) was given by intramuscular injection, once each day. For both groups, one menstrual cycle constituted one course. After two courses of treatment, follicular development condition, the changes of endometrial thickness and morphology, ovarian resistent index (RI) and pulsatility index (PI), rate of ovulation and pregnancy were compared between the two groups.
After the treatment, the average diameters of the biggest follicle increased in both groups, while the endometrial thickness and morphology in the plum-blossom needle group were superior to those in the medication group (all P < 0.05). Ovarian RI and PI during mature follicular phase in the plum-blossom needle group were inferior to those in the medication group (both P < 0.05). The differences in ovulation and pregnancy rate were not significant statistically between the two groups (both P > 0.05).
The plum-blossom needle therapy based on regulating Thoroughfare, Conception, Governor and Belt Vessel could improve the ovarian blood perfusion, promote the follicular growth, increase the ovulation rate of mature follicle and avoid the out-of-sync between growth of follicle and endometrium during the treatment of western medication.
观察梅花针治疗卵泡发育不良（FM）的临床疗效。
将50例卵泡发育不良患者随机分为梅花针组和药物组，每组25例。梅花针组在卵泡生长期沿任脉、督脉、冲脉、带脉及脾俞（BL20）、胃俞（BL21）、肾俞（BL23）、卵巢（奇穴）、子宫（EX-CA1）叩刺梅花针，隔日1次。药物组口服克罗米芬（CC），肌内注射人绒毛膜促性腺激素（HCG），每日1次。两组均以1个月经周期为1个疗程。治疗2个疗程后，比较两组卵泡发育情况、子宫内膜厚度及形态变化、卵巢阻力指数（RI）和搏动指数（PI）、排卵率及妊娠率。
治疗后，两组最大卵泡平均直径均增大，梅花针组子宫内膜厚度及形态优于药物组（均P<0.05）。梅花针组成熟卵泡期卵巢RI和PI低于药物组（均P<0.05）。两组排卵率及妊娠率差异无统计学意义（均P>0.05）。
基于调治冲脉、任脉、督脉、带脉的梅花针疗法可改善卵巢血液灌注，促进卵泡生长，提高成熟卵泡排卵率，避免西药治疗过程中卵泡与子宫内膜生长不同步。
